Singapore-based MediSix Therapeutics, which is developing cellular therapies targeting T-cell leukaemia and lymphoma, announced that it has raised $20 million in Series A financing backed by state investment arm Temasek Holdings.
Continue reading this story with a subscription to DealStreetAsia.
Unlock your competitive advantage in a rapidly evolving scape. Our packages come with exclusive access to archives, content, data, discount on summit tickets & more. Be a part of our growing community now.